Regeneron(REGN) GlobeNewswire News Room·2025-02-19 00:53Core Viewpoint - A class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. for allegedly misleading investors about its business prospects during the period from November 2, 2023, to October 30, 2024 [1][2]. Allegations - The lawsuit claims that Regeneron failed to disclose several key points, including: - Payments made to distributors to cover credit card fees, which were contingent on not charging Eylea customers more for credit card use [2] - These payments effectively subsidized the prices for customers using credit cards to purchase Eylea [2] - The price concessions led to a lower selling price for Eylea [2] - Retina practices were sensitive to higher prices for anti-VEGF medications, giving Regeneron a competitive advantage through these concessions [2] - The misleading reporting of Eylea sales due to these undisclosed payments [2] - Overstated Average Selling Price (ASP) reported to federal agencies, violating the False Claims Act [2] - Positive statements made by the company regarding its business and prospects were materially misleading [2] Next Steps for Investors - Shareholders interested in serving as lead plaintiffs must submit their applications by March 4, 2025 [3]. - Investors can choose to remain absent class members and still be eligible for recovery without participating in the case [3]. Company Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4].